Univariate analysis for OS and RFS in AML patients (n = 389) according to cohesin gene mutation status
| . | OS . | RFS . | ||||
|---|---|---|---|---|---|---|
| Endpoint . | HR . | 95% CI . | P . | HR . | 95% CI . | P . |
| Cohesin mutations combined | ||||||
| Cohesin mutated vs wild-type | 0.98 | 0.56-1.72 | .94 | 0.70 | 0.36-1.38 | .3 |
| Cohesin mutations separately | ||||||
| STAG1 mutated vs wild-type | 0.68 | 0.22-2.12 | .5 | 0.50 | 0.12-2 | .33 |
| STAG2 mutated vs wild-type | 1.53 | 0.57-4.11 | .4 | 1.26 | 0.4-3.93 | .7 |
| SMC3 mutated vs wild-type | 0.28 | 0.04-1.97 | .2 | 0.05 | 0-4.75 | .19 |
| RAD21 mutated vs wild-type | 1.47 | 0.47-4.60 | .51 | 1.02 | 0.25-4.1 | .98 |
| . | OS . | RFS . | ||||
|---|---|---|---|---|---|---|
| Endpoint . | HR . | 95% CI . | P . | HR . | 95% CI . | P . |
| Cohesin mutations combined | ||||||
| Cohesin mutated vs wild-type | 0.98 | 0.56-1.72 | .94 | 0.70 | 0.36-1.38 | .3 |
| Cohesin mutations separately | ||||||
| STAG1 mutated vs wild-type | 0.68 | 0.22-2.12 | .5 | 0.50 | 0.12-2 | .33 |
| STAG2 mutated vs wild-type | 1.53 | 0.57-4.11 | .4 | 1.26 | 0.4-3.93 | .7 |
| SMC3 mutated vs wild-type | 0.28 | 0.04-1.97 | .2 | 0.05 | 0-4.75 | .19 |
| RAD21 mutated vs wild-type | 1.47 | 0.47-4.60 | .51 | 1.02 | 0.25-4.1 | .98 |
HR >1 or <1 indicate an increased or decreased risk, respectively, of an event for the first category listed.
P, P value from univariate or multivariate Cox proportional hazards models.